A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

被引：7

作者：

Akaza, Hideyuki ^{[1
]}

Uemura, Hirotsugu ^{[2
]}

Tsukamoto, Taiji ^{[3
]}

Ozono, Seiichiro ^{[4
]}

Ogawa, Osamu ^{[5
]}

Sakai, Hideki ^{[6
]}

Oya, Mototsugu ^{[7
]}

Namiki, Mikio ^{[8
]}

Fukasawa, Satoshi ^{[9
]}

Yamaguchi, Akito ^{[10
]}

Uemura, Hiroji ^{[11
]}

Ohashi, Yasuo ^{[12
]}

Maeda, Hideki ^{[13
]}

Saito, Atsushi ^{[13
]}

Takeda, Kentaro ^{[13
]}

Naito, Seiji ^{[10
]}

机构：

[1] Univ Tokyo, Strateg Invest Comprehens Canc Network, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan

[2] Kinki Univ, Dept Urol, Fac Med, 377-2 Ono Higashi, Osakasayama 5898511, Japan

[3] Sapporo Med Univ, Dept Urol, Sch Med, S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[4] Hamamatsu Univ Sch Med, Dept Urol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan

[5] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan

[6] Nagasaki Univ, Dept Urol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[7] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[8] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan

[9] Chiba Canc Ctr, Dept Urol, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan

[10] Harasanshin Hosp, Div Urol, Hakata Ku, 1-8 Taihakumachi, Fukuoka 8120033, Japan

[11] Yokohama City Univ, Dept Urol & Renal Transplantat, Med Ctr, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan

[12] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan

[13] Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 21卷 / 04期

关键词：

Androgen receptor inhibitor; Enzalutamide; Metastatic castration-resistant prostate cancer; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CLINICAL ACTIVITY; DOCETAXEL; THERAPY; TRIAL; PREDNISOLONE; MITOXANTRONE; ANTIANDROGEN;

D O I：

10.1007/s10147-016-0952-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trial registration: ClinicalTrials.gov NCT01284920.

引用

页码：773 / 782

页数：10

共 50 条

[21] Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Lin, Jianqing
Elkon, Jacob
Ricart, Brittany
Palmer, Erica
Zevallos-Delgado, Christian
Noonepalle, Satish
Burgess, Brooke
Siegel, Robert
Ma, Yan
Villagra, Alejandro
ONCOLOGIST, 2021, 26 (12): : E2136 - E2142
[22] The changing landscape in metastatic castration-resistant prostate cancer
Leibowitz-Amit, Raya
Joshua, Anthony M.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2013, 7 (03) : 243 - 248
[23] Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer
Hori, Akiyo
Sahashi, Haruka
Sano, Sora
Matsumiya, Emiri
Ariga, Maho
Asano, Akari
Soda, Midori
Goto, Chitoshi
Mizui, Takashi
Komeda, Hisao
Kitaichi, Kiyoyuki
ANTICANCER RESEARCH, 2020, 40 (12) : 7101 - 7108
[24] Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
Caffo, Orazio
Ortega, Cinzia
Nole, Franco
Gasparro, Donatello
Mucciarini, Claudia
Aieta, Michele
Zagonel, Vittorina
Iacovelli, Roberto
De Giorgi, Ugo
Facchini, Gaetano
Veccia, Antonello
Palesandro, Erica
Verri, Elena
Buti, Sebastiano
Razzini, Giorgia
Bozza, Giovanni
Maruzzo, Marco
Ciccarese, Chiara
Schepisi, Giuseppe
Rossetti, Sabrina
Maines, Francesca
Kinspergher, Stefania
Fratino, Lucia
Ermacora, Paola
Nicodemo, Maurizio
Giordano, Monica
Sartori, Donata
Scapoli, Daniela
Sabbatini, Roberto
Lo Re, Giovanni
Morelli, Franco
D'Angelo, Alessandro
Vittimberga, Isabella
Lippe, Paolo
Carrozza, Francesco
Messina, Caterina
Galli, Luca
Valcamonico, Francesca
Porta, Camillo
Pappagallo, Giovanni
Aglietta, Massimo
EUROPEAN JOURNAL OF CANCER, 2021, 155 : 56 - 63
[25] Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program
Papazoglou, Dimitrios
Wannesson, Luciano
Berthold, Dominik
Cathomas, Richard
Gillessen, Silke
Rothermundt, Christian
Hasler, Loretta
Winterhalder, Ralph
Barth, Andreas
Mingrone, Walter
Nussbaum, Catrina Uhlmann
von Rohr, Lukas
von Burg, Philippe
Schmid, Mathias
Richner, Juerg
Baumann, Sylvia
Kuhne, Reto
Stenner, Frank
Rothschild, Sacha I.
CLINICAL GENITOURINARY CANCER, 2017, 15 (03) : E315 - E323
[26] Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
Noonan, K. L.
North, S.
Bitting, R. L.
Armstrong, A. J.
Ellard, S. L.
Chi, K. N.
ANNALS OF ONCOLOGY, 2013, 24 (07) : 1802 - 1807
[27] Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
Serritella, Anthony, V
Shevrin, Daniel
Heath, Elisabeth, I
Wade, James L.
Martinez, Elia
Anderson, Amanda
Schonhoft, Joseph
Chu, Yen-Lin
Karrison, Theodore
Stadler, Walter M.
Szmulewitz, Russell Z.
CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1549 - 1559
[28] Enzalutamide in castration resistant prostate cancer
Rios Gonzalez, Emilio
Martinez-Pineiro, Luis
ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (08): : 664 - 675
[29] What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Lebdai, Souhil
Basset, Victor
Branchereau, Julien
de La Taille, Alexandre
Flamand, Vincent
Lebret, Thierry
Murez, Thibaut
Neuzillet, Yann
Ploussard, Guillaume
Audenet, Francois
WORLD JOURNAL OF UROLOGY, 2016, 34 (05) : 617 - 624
[30] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
Zhang, Tian
Zhu, Jason
George, Daniel J.
Armstrong, Andrew J.
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485

← 1 2 3 4 5 →